MANKIND PHARMA
MANKINDVerifiedMANKIND PHARMA is a publicly traded security listed on the NSE/BSE exchange.
Stock Snapshot & Key Numbers — MANKIND PHARMA
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
MANKIND PHARMA (MANKIND) is a Indian equity security listed on the NSE/BSE with ISIN BSE:543904. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹2275.50, recording a -72.10 (-3.07%) decline from its previous close of ₹2347.60. Over the trailing 52-week trading cycle, MANKIND has traded between a 52-week low of ₹1927.40 and a 52-week high of ₹2617.90, establishing its annual trading channel. In historical performance, MANKIND PHARMA has fallen 7.32% over the past 1 year. Period returns across standard measurement intervals include: 1-week: -3.93%, 1-month: +1.31%, 6-month: +8.13%, 1-year: -7.32%, 3-year: +25.42%, 5-year: +59.99%. Daily reported trading volume reached 8,89,731 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 47.9x and a price-to-book (P/B) ratio of 6.0x, with a trailing dividend yield of 0.00%. Its market capitalization stands at ₹97,829.73 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)
How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +0.64 | +0.32 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +0.64% co-movement (correlation: 0.32). Descriptive historical relationship, not predictive. |
| USD / INR | -0.50 | -0.14 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.50% co-movement (correlation: -0.14). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.07 | -0.15 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.07% co-movement (correlation: -0.15). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | -0.05 | -0.03 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.05% co-movement (correlation: -0.03). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹2,368.50 | ₹2,275.50 | -3.93% |
| 15 Days | ₹2,535.00 | ₹2,275.50 | -10.24% |
| 1 Month | ₹2,246.00 | ₹2,275.50 | +1.31% |
| 3 Months | ₹2,546.00 | ₹2,275.50 | -10.62% |
| 6 Months | ₹2,104.40 | ₹2,275.50 | +8.13% |
| 1 Year | ₹2,455.30 | ₹2,275.50 | -7.32% |
| 3 Years | ₹1,814.25 | ₹2,275.50 | +25.42% |
| 5 Years | ₹1,422.30 | ₹2,275.50 | +59.99% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹2,164.60 | ₹2,275.50 | +5.1% | |
| CY 2025 | ₹2,881.05 | ₹2,196.50 | -23.8% | |
| CY 2024 | ₹1,979.20 | ₹2,880.40 | +45.5% | |
| CY 2023 | ₹1,422.30 | ₹1,982.50 | +39.4% |
Historical Investment Simulator
Factual simulation of past returns in MANKIND PHARMA (MANKIND) using real recorded closing prices.
Corporate Actions History
No dividend or stock split distributions recorded in historical feeds for MANKIND.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Mankind Pharma shares fall 6% despite 30% Q1 PAT growth; here's why - Business Standard
Mankind Pharma shares fall 6% despite 30% Q1 PAT growth; here's why Business Standard
Mankind Pharma Share Price Falls Over 5% Even As Q1 Profit Rises 29% - NDTV Profit
Mankind Pharma Share Price Falls Over 5% Even As Q1 Profit Rises 29% NDTV Profit
Mankind Pharma Ltd (NSE:MANKIND) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Mankind Pharma Ltd (NSE:MANKIND) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... Yahoo Finance
Mankind Pharma Posts Q4 FY26 Results With 12% Revenue Growth And Higher Margins - BW Healthcare
Mankind Pharma Posts Q4 FY26 Results With 12% Revenue Growth And Higher Margins BW Healthcare
Mankind Pharma Q4 revenue rises 12%; chronic therapies drive margin expansion - CNBC TV18
Mankind Pharma Q4 revenue rises 12%; chronic therapies drive margin expansion CNBC TV18
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Operating performance or EBITDA margins lagged market expectations, triggering multiples compression.
- •Direct quantitative change registered at 6%
- •Top-line revenue or operating profitability registered contraction vs previous comparative period
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
Company filings and balance-sheet numbers show steady day-to-day operations with stable margins and working capital.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About MANKIND PHARMA (MANKIND)
Key facts on MANKIND share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of MANKIND PHARMA (MANKIND)?
As of 16 Oct 2026, the official closing share price of MANKIND PHARMA (MANKIND) on NSE/BSE is ₹2,275.50 (-3.07% vs the previous close). Over the past 52 weeks, MANKIND has traded between a low of ₹1,927.40 and a high of ₹2,617.90, with a reported market capitalization of ₹97,829.73 Cr.
What are the historical returns of MANKIND PHARMA (MANKIND)?
Based on split-adjusted closing prices through 16 Oct 2026, MANKIND PHARMA (MANKIND) recorded the following trailing price returns: 1 Week: -3.93% (from ₹2,368.50 to ₹2,275.50); 15 Days: -10.24% (from ₹2,535.00 to ₹2,275.50); 1 Month: +1.31% (from ₹2,246.00 to ₹2,275.50); 3 Months: -10.62% (from ₹2,546.00 to ₹2,275.50); 6 Months: +8.13% (from ₹2,104.40 to ₹2,275.50); 1 Year: -7.32% (from ₹2,455.30 to ₹2,275.50); 3 Years: +25.42% (from ₹1,814.25 to ₹2,275.50); 5 Years: +59.99% (from ₹1,422.30 to ₹2,275.50). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of MANKIND PHARMA (MANKIND)?
MANKIND PHARMA (MANKIND) currently trades at a trailing Price-to-Earnings (P/E) ratio of 47.9x, a Price-to-Book (P/B) ratio of 6.0x, and a trailing 12-month dividend yield of 0.00%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in MANKIND have grown?
Based on historical closing prices for MANKIND PHARMA (MANKIND): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹1,59,987.34 (+60.0% total return, 14.6% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹4,20,000.00) would be worth ₹4,42,116.85 (+5.3% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.